Product Description
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Fallopian Tube Cancer|Glioblastoma|Peritoneal Cancer|Breast Cancer|Ovarian Cancer
Phase 1: Non-Small-Cell Lung Cancer|Colorectal Cancer|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GLYRad | P2 |
Completed |
Glioblastoma |
2019-08-01 |
|
I1D-MC-JIAE | P2 |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
2017-05-25 |
|
I4D-MC-JTJL | P1 |
Completed |
Non-Small-Cell Lung Cancer|Colorectal Cancer |
2017-05-15 |
|
OLYMPE | P2 |
Terminated |
Breast Cancer |
2017-04-01 |